Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Biotech
Pfizer CEO makes case for $6B bet on 'fabulous' bispecific
Albert Bourla pulled back the curtain on his PD-1xVEGF bispecific bet, revealing the lengths his team went to to gain reassurance about Chinese data.
Nick Paul Taylor
Jun 10, 2025 9:56am
FDA refuses Axsome filing for former Pfizer fibromyalgia asset
Jun 9, 2025 12:27pm
Pharma-backed dementia fund raises $269M to invest in therapies
May 20, 2025 9:48am
Former Pfizer antibody reduces cardio risk marker in ph. 2
May 20, 2025 7:30am
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific
May 20, 2025 4:47am
Arvinas lays off 33% of staff, axes Pfizer-partnered trials
May 1, 2025 8:50am
